- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Poor Guidelines Compliance Suspected Cause of Most Metastatic GCT Relapses
A retrospective study suggests that the majority of cases of metastatic germ cell tumor (GCT) relapse are due primarily to poor conformity to international treatment guidelines, not to aggressive tumor biology (Abstract 323). This is sobering news considering that 80% of patients with metastatic GCT can be cured when treated appropriately.
The study focused on 78 patients with metastatic GCT that progressed after initial chemotherapy, all of whom were referred to the Institut Gustave Roussy in France between 2000 and 2010 for additional care.
Strikingly, only about half of these individuals (49%) received first-line treatment in accord with international treatment guidelines that were available at the time of disease diagnosis. The most common violations included delays between the delivery of chemotherapy cycles and the indication and timing of postchemotherapy surgery.
Guidelines compliance was markedly higher among patients initially treated at cancer centers as opposed to public or private hospitals (71% vs. 22%, respectively; p = 0.00001). In fact, the only independent predictive factor for guidelines compliance identified was the type of original treatment center (p = 0.00005).
Read more about the study at:http://tinyurl.com/83tshh6
Source: OBR Daily.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More
